ATS Business Model and Strategic M&A Impact
21
2 Reconciliation of previously reported amounts due to measurement period adjustments in Q3 F2022
As disclosed in the Company's Interim Condensed Consolidated Financial Statements for the period ended December 26, 2021, certain amounts for the previously reported six months
ended September 26, 2021 were re-presented as a result of measurement period adjustments for the acquisitions of CFT, BioDot and NCC, as required by IFRS 3 - Business
Combinations.
For clarity, the adjustments are summarized below. There were no changes to Adjusted Earnings from Operations, Adjusted EBITDA, or Cash Flows Provided by Operating Activities
as reported in the Company's Management Discussion and Analysis for the Quarter Ended December 26, 2021.
(C$ mm, except per share amounts)
Q1
F2022
Q2
Q3
Q4
F2022 F2022 F2022
F2022
51.9
55.4
38.2
59.8
Earnings from operations (originally presented)
Re-presented amounts at Q3 F2022
Acquisition-related inventory fair value charges¹
(5.6)
(9.7)
Amortization of acquisition-related intangible assets²
(1.4)
(2.0)
Earnings from operations (re-presented at Q3 F2022)
44.9
43.7
38.2
59.8
186.6
Finance costs and provision for income taxes (originally presented)
(18.1)
(17.0)
(14.9) (19.9)
Tax on re-presented amounts at Q3 F2022
1.9
2.9
Net income (re-presented at Q3 F2022)
28.7
29.6
23.3
39.9
121.43
Net income (originally presented)
33.9
38.4
23.3
39.9
Net income change
(5.2)
(8.8)
Basic and diluted earnings per share
Re-presented at Q3 F2022
0.31
0.32
0.25
0.43
1.32
Originally presented
0.37
0.41
0.25
0.43
EPS change
(0.06)
(0.09) (0.00)
(0.00)
1. Adjustment included in Cost of revenues 2. Adjustment included in Selling, general and administrative 3. Totals may differ due to roundingView entire presentation